HIGHTIDE THERAPEUTICS, INC.

News HighTide Therapeutics, Inc.

Equities

2511

KYG4568L1023

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
4.48 ^HKD	+0.45%		-12.33%	-65.43%

May. 21	108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.	CI
Apr. 03	HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...	Jun. 07	EQ
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study	Jun. 05	AQ
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)	Jun. 04	AQ
108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.	May. 20	CI
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator	Apr. 03	MT
Hightide Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase IIb Clinical Trial Evaluating HTD1801	Apr. 03	CI
HighTide Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
HighTide Therapeutics, Inc. Announces Resignation of Mr. LI LI as A Non-Executive Director	Feb. 02	CI
HighTide Therapeutics to Set Up New Plant in China Expansion Plans	Jan. 22	MT
China's Curbs on Game Spending Pulls Down Hong Kong Stocks; One Out of Four Trading Debutants Drop at Close	Dec. 22	MT
Hightide Therapeutics Gains 7% in Hong Kong Trading Debut	Dec. 22	MT
HighTide Therapeutics, Inc. has completed an IPO in the amount of HKD 278.231 million.	Dec. 21	CI
HighTide Therapeutics, Inc. announced that it has received CNY 100 million in funding from Cangzhou Chuangrong Equity Investment Fund Co., Ltd.	Dec. 16	CI
HighTide Therapeutics, Inc. has filed an IPO in the amount of HKD 278.231 million.	Dec. 13	CI
HighTide Therapeutics, Inc. Appoints Edmund Sim as Chief Financial Officer	23-02-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
2511 Stock
News HighTide Therapeutics, Inc.

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer